Sensus Healthcare (NASDAQ:SRTS) Price Target Raised to $11.00

Sensus Healthcare (NASDAQ:SRTS) had its price objective increased by HC Wainwright from $10.00 to $11.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2024 earnings at $0.11 EPS, FY2024 earnings at $0.42 EPS, Q1 2025 earnings at $0.14 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.52 EPS.

Separately, Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Stock Up 6.9 %

NASDAQ SRTS opened at $8.94 on Monday. The firm’s 50-day simple moving average is $6.47 and its two-hundred day simple moving average is $6.03. Sensus Healthcare has a 52 week low of $2.05 and a 52 week high of $9.20. The company has a market cap of $146.53 million, a PE ratio of 15.60 and a beta of 1.04.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Truvestments Capital LLC acquired a new stake in shares of Sensus Healthcare in the third quarter worth approximately $32,000. Chapin Davis Inc. purchased a new position in shares of Sensus Healthcare during the 2nd quarter worth approximately $53,000. XTX Topco Ltd acquired a new stake in Sensus Healthcare during the 2nd quarter valued at $95,000. Hillsdale Investment Management Inc. acquired a new stake in shares of Sensus Healthcare during the first quarter worth $155,000. Finally, Cubist Systematic Strategies LLC purchased a new position in Sensus Healthcare in the second quarter valued at about $156,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.